DexCom, Inc. (NASDAQ:DXCM) Shares Bought by D.A. Davidson & CO.

Posted by Defense World Staff on Jul 11th, 2023

D.A. Davidson & CO. lifted its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 0.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,219 shares of the medical device company’s stock after purchasing an additional 125 shares during the quarter. D.A. Davidson & CO.’s holdings in DexCom were worth $3,511,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Norges Bank acquired a new position in DexCom during the 4th quarter worth approximately $421,378,000. Jennison Associates LLC lifted its holdings in DexCom by 32.3% in the fourth quarter. Jennison Associates LLC now owns 9,186,222 shares of the medical device company’s stock valued at $1,040,248,000 after acquiring an additional 2,242,846 shares during the period. Alphabet Inc. purchased a new stake in shares of DexCom during the 3rd quarter worth $161,080,000. 1832 Asset Management L.P. acquired a new position in shares of DexCom during the 4th quarter worth $151,538,000. Finally, Clearbridge Investments LLC increased its holdings in shares of DexCom by 304.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock valued at $674,329,000 after purchasing an additional 992,049 shares in the last quarter. 93.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on DXCM shares. TheStreet cut shares of DexCom from a “b-” rating to a “c+” rating in a report on Thursday, May 25th. Stifel Nicolaus raised their price objective on DexCom from $130.00 to $140.00 in a research note on Friday, April 28th. Barclays upped their target price on DexCom from $110.00 to $115.00 in a report on Monday, May 1st. Raymond James raised their target price on shares of DexCom from $138.00 to $140.00 in a report on Friday, April 28th. Finally, Citigroup upped their price target on shares of DexCom from $146.00 to $150.00 in a report on Monday. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $128.06.

Insider Activity at DexCom

In other DexCom news, EVP Jacob Steven Leach sold 30,764 shares of the firm’s stock in a transaction dated Thursday, April 20th. The stock was sold at an average price of $125.00, for a total transaction of $3,845,500.00. Following the transaction, the executive vice president now directly owns 259,613 shares in the company, valued at $32,451,625. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Jacob Steven Leach sold 30,764 shares of DexCom stock in a transaction that occurred on Thursday, April 20th. The stock was sold at an average price of $125.00, for a total transaction of $3,845,500.00. Following the sale, the executive vice president now owns 259,613 shares of the company’s stock, valued at approximately $32,451,625. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jereme M. Sylvain sold 2,400 shares of DexCom stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $117.58, for a total transaction of $282,192.00. Following the sale, the chief financial officer now owns 74,711 shares in the company, valued at $8,784,519.38. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,512 shares of company stock valued at $5,918,379. Insiders own 0.41% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $130.62 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.02 and a quick ratio of 1.82. DexCom, Inc. has a one year low of $73.93 and a one year high of $134.14. The business’s 50-day moving average price is $122.74 and its two-hundred day moving average price is $116.68. The company has a market capitalization of $50.63 billion, a P/E ratio of 186.60, a price-to-earnings-growth ratio of 2.94 and a beta of 1.15.

DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings data on Thursday, April 27th. The medical device company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.02. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $720.52 million. DexCom had a return on equity of 18.29% and a net margin of 9.68%. The firm’s revenue was up 1085.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.08 earnings per share. Analysts anticipate that DexCom, Inc. will post 1.07 earnings per share for the current fiscal year.

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.